US20040096420A1 - Compositions and methods for treating baldness - Google Patents

Compositions and methods for treating baldness Download PDF

Info

Publication number
US20040096420A1
US20040096420A1 US10624078 US62407803A US2004096420A1 US 20040096420 A1 US20040096420 A1 US 20040096420A1 US 10624078 US10624078 US 10624078 US 62407803 A US62407803 A US 62407803A US 2004096420 A1 US2004096420 A1 US 2004096420A1
Authority
US
Grant status
Application
Patent type
Prior art keywords
composition
percent
extract
minoxidil
comprises
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10624078
Inventor
Chris Catalfo
Fred Mussari
Original Assignee
Chris Catalfo
Fred Mussari
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILET PREPARATIONS
    • A61Q7/00Preparations for affecting hair growth
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/683Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716Glucans
    • A61K31/724Cyclodextrins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/11Pteridophyta or Filicophyta (ferns)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/16Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/23Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/28Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/42Cucurbitaceae (Cucumber family)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/53Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/534Mentha (mint)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/53Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/537Salvia (sage)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/70Polygonaceae (Buckwheat family), e.g. spineflower or dock
    • A61K36/704Polygonum, e.g. knotweed
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/73Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/734Crataegus (hawthorn)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/886Aloeaceae (Aloe family), e.g. aloe vera
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/889Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/19Cosmetics or similar toilet preparations characterised by the composition containing inorganic ingredients
    • A61K8/25Silicon; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/30Cosmetics or similar toilet preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toilet preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34Alcohols
    • A61K8/342Alcohols having more than seven atoms in an unbroken chain
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/30Cosmetics or similar toilet preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toilet preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494Cosmetics or similar toilet preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/30Cosmetics or similar toilet preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toilet preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494Cosmetics or similar toilet preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4953Cosmetics or similar toilet preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/30Cosmetics or similar toilet preparations characterised by the composition containing organic compounds
    • A61K8/55Phosphorus compounds
    • A61K8/553Phospholipids, e.g. lecithin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/30Cosmetics or similar toilet preparations characterised by the composition containing organic compounds
    • A61K8/63Steroids; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/30Cosmetics or similar toilet preparations characterised by the composition containing organic compounds
    • A61K8/67Vitamins
    • A61K8/673Vitamin B group
    • A61K8/675Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/72Cosmetics or similar toilet preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73Polysaccharides
    • A61K8/738Cyclodextrins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/92Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A61K8/922Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/96Cosmetics or similar toilet preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toilet preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof

Abstract

Disclosed herein are novel compositions and/or formulations containing minoxidil as an active ingredient in combination with other active agents and/or enhancer agents (e.g., saw palmetto extract and nettle root extract) which increase the hair growth capability of the composition. Also disclosed are methods of using the novel compositions to treat male patterned baldness and to stimulate hair growth on the scalp, including both the apex and frontal regions of the scalp.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This application is a continuation of co-pending U.S. application Ser. No. 09/789,294, filed Feb. 20, 2001 which claims the benefit under 35 USC § 119(e) of Provisional Application No. 60/183553 filed Feb. 18, 2000, the disclosures of which are incorporated herewith in their entirety.[0001]
  • BACKGROUND OF THE INVENTION
  • Androgenic alopecia is the single largest type of recognizable alopecia to affect both men (50%) and women (30%), primarily of Caucasian origin. Androgenic alopecia or common baldness represents 99 percent of all cases of hair loss (Brodland and Muller, 1991). The condition is characterized by the gradual conversion of terminal hair to short, wispy, colorless vellus hair. [0002]
  • It is generally accepted that genetic hair loss arises from an inherited predisposition activated by circulating androgenic hormones. While many investigators have tried to isolate the causative androgen metabolite, no single molecule has emerged. For example, in comparative studies between non-balding controls, no significant difference between mean hormonal values or amounts has been detected. See Puolakka, 1980. This suggests that a sensitivity or receptivity to hormones at the cell binding sites within the dermal papilla is a possible factor. Several treatments are based on this theory using anti-androgens such as CPA (cyproterone acetate) in combination with ethinyl-estradiol and the aldosterone antagonist spironolactone, which, given in dosages from 75 to 100 mg per day has shown some benefit. See e.g., Rushton and Ramsay, 1992; Rushton et al. 1991. [0003]
  • Most treatment modalities currently employed (such as hair transplantation) have been performed based on the theory that some hair follicles are genetically predisposed for sensitivity to androgens in the body. However, transplantation methods can be painful and expensive, often resulting in an undesirable “fake” appearance. No single treatment modality has proven completely or repeatably successful in inducing, maintaining and/or increasing hair growth. [0004]
  • In 1980, the reversal of androgenic alopecia in a male patient receiving minoxidil for hypertension was revealed and minoxidil has since been used to promote hair growth, most commonly by topical application (Zapacosta, 1980). Minoxidil's vasodilating effect on the scalp is one of the proposed mechanisms by which minoxidil promotes hair growth. However, despite its popularity, minoxidil has not performed in a completely satisfactory fashion in promoting hair growth in all target populations. While minoxidil has been shown to stimulate some hair growth at the apex region of the scalp, hair growth at the frontal region of the scalp, for the most part, has not been shown to be improved by minoxidil treatment alone. [0005]
  • Cosmetic treatment of age-related hair loss in androgenic alopecia patients with topical solutions of minoxidil (ROGAINE®) alone, or in combination with skin penetration enhancers, such as DMSO, has resulted in only moderate regrowth of hair in less than 40% of such patients (Katz, 1988). Moreover, treatments with topical solutions of minoxidil require multiple applications of the active ingredient each day, which can be very inconvenient as well as expensive. [0006]
  • There is a need for methods of treating hair loss that require fewer applications of active ingredient, e.g., minoxidil, and which will also provide hair regrowth sooner, in more abundance, and thicker, than is presently observed using minoxidil and known penetration enhancers. Further, there is a need for a hair loss treatment which can improve hair growth at the frontal as well as apex regions of the scalp. [0007]
  • BRIEF SUMMARY OF THE INVENTION
  • The subject invention pertains to novel compositions and/or formulations containing minoxidil as an active ingredient in combination with other active agents and/or enhancer agents which increases the hair growth capability of the composition. Another aspect of the subject invention pertains to methods of using the novel compositions to treat male patterned baldness and to stimulate hair growth on the scalp, including both the apex and frontal regions of the scalp. In addition to, or in place of minoxidil, glycerol oxido esters and/or ketoconazole can be added to the subject hair growth compositions. [0008]
  • According to one aspect, the subject invention pertains to a topical composition designed for application to the scalp wherein said composition comprises, in admixture with a pharmaceutically acceptable carrier and minoxidil, one or more of the following components: saw palmetto extract; nettle root extract; Capsaicin; Niacin; Gingko Biloba; horsetail extract; phospolipid; glycero oxido esters; ursolic acid; ketoconazole; 1,4:3,6 dianhydro-2.5-di-o-methyl-D-glucitol; cycoldextrin; peppermint oil; or milk thistle. A particular aspect of the subject invention pertains to a composition for treating androgenic alopecia comprising minoxidil in combination with saw palmetto extract. A further aspect of the subject invention preferably comprises, in addition to the minoxidil and saw palmetto extract, a nettle root extract. [0009]
  • The subject compositions and methods provide a safe and effective way to increase hair growth of the scalp. These and other advantageous aspects of the subject invention are described in further detail below. [0010]
  • DETAILED DISCLOSURE OF THE PREFERRED EMBODIMENTS
  • The subject invention is directed to novel compositions and methods of using the same for treating androgenic alopecia, or male pattern baldness. The subject compositions comprise minoxidil as one active component in combination with other compounds which act in combination with minoxidil to synergistically increase the effectiveness of the composition. As used herein “minoxidil” refers to 2,4,pyrimidihediamine6-(1-piperdinyl)-3-oxide, and analogs and salts thereof, as described in U.S. Pat. Nos. 4,139,619; 4,596,812; and 5,030,442 which are incorporated herein by this reference. Alternatively, glycerol oxido esters, ketoconazole, or a combination thereof can be substituted for minoxidil, or otherwise added to the subject compositions in addition to minoxidil. [0011]
  • One embodiment of the subject invention is directed to a composition comprising minoxidil and saw palmetto extract in combination with at least one other inert compound whereby said composition is in a pharmaceutically-acceptable form suitable for topical administration. Conventional pharmaceutical forms for this purpose include ointments, waxes, gels, lotions, pastes, jellies, sprays, aerosols, and the like in aqueous or nonaqueous formulations. The term “ointment” embraces formulations (including creams) having oleaginous, absorption, water-soluble and emulsion-type bases, e.g., petrolatum, lanolin, polyethylene glycols, N-methyl-2-pyrrolidinone, oleyl alcohol as well as mixtures of these. In an alternative embodiment, the subject invention is directed to a composition comprising minoxidil in combination with a nettle root extract. [0012]
  • Some evidence suggests that saw palmetto extract can act as a DHT inhibitor. The term “DHT inhibitor” is used herein in its broad sense and relates to substances that inhibit enzymes responsible for producing dihydrotestosterone, such as 5-α-reductase, or otherwise block or mask activity of DHT by binding to DHT thereby inactivating it and/or binding to DHT receptors. In addition to, or in place of saw palmetto extract, other DHT inhibitors can be provided in the subject compositions, including, but not limited to, nettle root extract, azelaic acid (see e.g., U.S. Pat. No. 5,925,679), and ginko biloba. [0013]
  • In a more preferred embodiment, the subject composition comprises minoxidil, saw palmetto extract, and nettle root extract, wherein the composition comprises about 1% to about 5% minoxidil, about 3% to about 8% saw palmetto extract, and about 1% to about 3% nettle root extract. [0014]
  • Diffusional resistance of the stratum corneum to topically applied agents has been demonstrated with various drugs. In order to overcome this barrier effect a number of compounds can be added to the subject compositions to enhance the transdermal delivery of drugs, such as dimethyl sulfoxide (DMSO); polyethylene glycol monolaurate; alkyl lactams; long chain amides, substituted 1,3-dioxacyclopentanes and substituted 1,3-dioxacyclohexanes; 1,4:3,6 dianhydro-2.5-di-o-methyl-D-glucitol; or mixtures thereof. For example, U.S. Pat. No. 3,551,554 discloses DMSO, U.S. Pat. No. 3,989,816 discloses 1-substituted azacycloheptane-2-one, U.S. Pat. No. 4,132,781 discloses a topical antibiotic composition containing 2-pyrrolidone or an n-lower alkyl-2-pyrrolidone, U.S. Pat. No. 4,017,641 discloses propylene glycol and 2-pyrrolidone-containing compositions and U.S. Pat. No. 4,861,764 discloses 1,3-dioxolane and 1,3-dioxane derivatives as percutaneous absorption enhancers, U.S. Pat. No. 4,082,881 discloses 1,4,3,6 dianhydro-2,5,-di-o-methyl-D-glucitol (see also Barry, [0015] Pharm. Pharmocol., 39:535-546 (1987)). WO 92/16236 discloses methods and compositions for enhancing the rate of absorption of topically administered physiologically active compounds. Minoxidil is disclosed as one of these compounds. Also, the penetration enhancers can be amino alcohol derivatives which may form a 1,3-dioxane ring.
  • Another example of an enhancing agent is 1,3-dioxacycloalkane taught, for example, in U.S. Pat. No. 5,620,980 whose teachings are incorporated herein by reference. Other agents include retin A or derivatives thereof such as tretinoin. [0016]
  • Other compounds which work to increase circulation to the cells of the scalp may be added to the subject compositions. These compounds are believed to not only increase health of the cutaneous and subcutaneous tissue of the scalp, but to aid in the delivery and penetration of active components as well. Compounds aiding in circulation which may be used in accord with the teachings herein include, but are not limited to, thistle, Ginkgo Biloba, and peppers (e.g., Cayenne pepper and Red pepper), ursolic acid (disclosed in Jap. Pat. No. 05286835, and Sattar et al., Pharmazie, 50:62-65 (1995)), or combinations thereof. [0017]
  • Some have hypothesized that there is a chronic inflammatory process, subtending to the hair bulbs, in patterned alopecia, leading to eventual scarring of the lower follicle, making regrowth impossible. To counter this inflammatory degenerative process, anti-inflammatories may also be added to the subject compositions. Such anti-inflammatories include steroidal as well as non-steroidal anti-inflammatories. Examples of anti-inflammatory agents useful in accord with the teachings herein include corticosteroids, ibuprofen and derivatives thereof, aspirin and derivatives thereof, aloe vera, and combinations thereof. The concentrations of steroidal compounds are preferably 0.5% to 2.5% of the subject composition. The concentration of non-steroidal compounds is preferably from about 1% to about 5%. [0018]
  • Antimicrobials may also be added to the subject compositions for treating alopecia. Examples of antimicrobials include, but are not limited to, organic solvents (e.g., alcohols) and oils or extracts (e.g., oil of wintergreen and peppermint oil), ursolic acid, or combinations thereof. [0019]
  • Compounds to aid in repair of hair, nails, and skin may also be added to the subject compositions. Examples of such compounds include selenium and silica, which may be added in relatively isolated form or in the form of various partially processed plant material or extracts (e.g., Horsetail-plantain or nettle root extract). [0020]
  • In a topical application, the compound or formulated composition can be applied to the area to be treated, in mammals such as the scalp in humans, by spraying, dabbing or swabbing. Other less specific methods can be employed provided the active ingredient(s) are delivered to the region of a hair follicle. Preferably, the compound or formulated composition is periodically applied to the treatment area on a routine basis prior to, during and subsequent to hair growth. Generally, the routine treatment would be to apply the compound or formulated composition at least daily, preferably twice daily although more frequent applications can be used. The percentage by weight of the active ingredients minoxidil or other vasodilator herein utilized range at an effective amount which is an amount sufficient to increase normal hair growth or treat various forms of alopecia whereby the hair growth is significantly more than if either of the compounds were solely administered. In topical preparations the pharmaceutical carrier for topical applications constitutes a major amount of the preparation. Typically, the active ingredient is in a range of from about 0.01 to about 10 percent total weight of the topical composition, preferably 0.1 to 5 percent total weight. [0021]
  • Pharmaceutically acceptable salts of minoxidil or other vasodilators taught herein are for example acid addition salts which may be chosen from the following: acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfitte, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodeclsulfate, ethanesultonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, pamoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, and undecanoate. [0022]
  • Pharmaceutically acceptable cationic addition salts of minoxidil or other vasodilators include: pharmacologically acceptable metal cations, ammonium, amine cations, or quaternary ammonium cations. Especially preferred metal cations are those derived from the alkali metals, e.g., lithium, sodium, and potassium, and from the alkaline earth metals, magnesium and calcium, although cationic forms of other metals, e.g., aluminum, zinc, and iron are also within the scope of this invention. Pharmacologically acceptable amine cations are those derived from primary, secondary, and tertiary amines. [0023]
  • The composition of the invention may be administered topically in a water-base cream, ointment, or gel form. Several factors contribute to cosmetic advantages of the water-base composition. High drug loading up to 5% or more in non-crystalline form is possible, and the drug remains in a non-crystalline form up to several hours or more after administration, since solvent evaporation is relatively slow and evaporation can occur without leading to drug crystallization. Since the composition contains little or no alcohol, it can be applied without stinging. [0024]
  • The drug is efficiently taken up by the skin, by virtue of the selected amphipath, and different rates of uptake can be achieved by varying the drug or amphipath concentration, and by selection of different amphipathic compounds. [0025]
  • The water-base composition may additionally contain liposome or lipid-emulsion particles in which the drug can be entrapped in non-crystalline form. See U.S. Pat. Nos. 4,485,054 and 4,761,288 for teachings on methods of encapsulating minoxidil in multilamellar lipid vesicles to aid in drug delivery. In one embodiment, a concentrated liposomal composition having desired cream or ointment consistency can be formulated using a novel solvent injection system. The liposome formulation can have high loading, and a rate of drug uptake can be modulated by choice of lipid components and relative molar amounts of lipid and drug. The lipid formulation is also expected to have the known moisturizing benefits of topical lipid formulations. In addition or alternatively, liposomes are loaded with saw palmetto extract and/or nettle root extract. [0026]
  • In another embodiment, the composition is dispersed as an aerosol form, such as in a chlorofluorocarbon solvent, for delivery in spray form. The spray form has many advantages of the water-base formulation, including high drug loading and enhanced drug uptake. Additionally, the spray composition has the advantage that it can be applied in a more convenient manner and without matting the hair in the treated scalp region. [0027]
  • Other suitable additives/carriers that may be admixed with the minoxidil composition include, but are not limited to, water, glycols, esters, glycerine, alcohols, lipid materials, coloring agents, fragrances, anti-oxidants, thickening agents, ultra-violet light stabilizers, preservatives, and other pharmaceutically accepted additives. [0028]
  • The selection of additives may impact on the effectiveness of the composition. A particularly preferred safe and effective composition is based on a cosmetic carrier wherein a solvent system is an aqueous alcoholic solution containing ethanol, propanol or isopropanol, together with a lower alkyl(C[0029] 1-C4)glycol, such as ethylene glycol or propylene glycol and, usually, a thickener or gelling agent. Another, often useful additive is dimethicone or other volatile silicone solvent and carrier.
  • In a specific embodiment, the subject hair growth compositions can be provided in shampoo and/or conditioner form, which can preferably be used on a daily basis. The subject compositions can be added to shampoo formulations commonly used in the art and readily produce by one skilled in the art. In a preferred embodiment, mixtures of fatty acid esters of sorbitol and sorbitol anhydrides (commonly called polysorbates) are added to the shampoo formulations. These compounds have nonionic properties that inhibit shedding of hair. Polysorbates are one of a group of nonionic surfactants obtained by esterifcation of sorbitol with one or three molecules of a fatty acid (e.g. stearic, lauric, oleic, palmitic) under conditions which cause splitting out of water from the sorbitol, leaving sorbitan. In an even more preferred embodiment ethylene oxide is added along with the fatty acid esters in the condensation reaction to effect water solution. [0030]
  • In an alternative embodiment, the components of the subject hair growth composition can be administered orally as a safe dietary supplement. Preferably, the dietary supplement is taken concurrent to administration of the topical compositions described herein. [0031]
  • The subject hair growth stimulating compositions can be packaged in a kit with instructions for use and applicators commonly used in the art. The subject compositions can be contained in various bottles having engaged thereto spray nozzles for administrating the composition to the affected area. [0032]
  • The teachings of all patents and publications cited throughout this specification are incorporated by reference in their entirety to the extent not inconsistent with the teachings herein. [0033]
  • Following are examples which illustrate procedures for practicing the invention. These examples should not be construed as limiting. All percentages are by weight and all solvent mixture proportions are by volume unless otherwise noted. Where percentages do not amount to 100 percent, DI water is added to the formulation to meet the remaining percentages.[0034]
  • EXAMPLE 1 Hair Growth Stimulating Formulation for Topical Administration
  • [0035]
    pharmaceutically-acceptable 35% to 99%
    carrier
    Minoxidil 1% to 5%
    Extract of Nettle Root 1% to 3%
    Saw Palmetto Extract 3% to 8%
  • EXAMPLE 2 Hair Growth Stimulating Formulation for Topical Administration
  • [0036]
    pharmaceutically-acceptable 35% to 99%
    carrier
    Minoxidil 1% to 5%
    Dimethyl Isosorbide 1% to 6%
    Capsaicin 0.5% to 2.5%
    Niacin 0.5% to 1.5%
    Ginkgo Biloba 1% to 3%
    Extract of Nettle Root 1% to 3%
    Horsetail Extract 2% to 4%
    Saw Palmetto Extract 3% to 8%
    Peppermint Oil 1% to 9%
    Milk Thistle 2% to 8%
    Methyl Nicotinate 0.5% to 4%
  • EXAMPLE 3 Hair Growth Stimulating Formulation for Topical Administration
  • [0037]
    Aloe Vera Gel 35% to 99%
    Minoxidil 1% to 5%
    Dimethyl Isosorbide 1% to 6%
    Rosemary Extract 2% to 8%
    Glycolic Acid 2% to 6%
    Pantothenic Acid 1% to 3%
    Glycerine 10% to 12%
    Safflower Oil 8% to 16%
    Capsaicin 0.5% to 2.5%
    Niacin 0.5% to 1.5%
    Ginkgo Biloba 1% to 3%
    Extract of Nettle Root 1% to 3%
    Horsetail Extract 2% to 4%
    Saw Palmetto Extract 3% to 8%
    Peppermint Oil 1% to 9%
    Milk Thistle 2% to 8%
    Methyl Nicotinate 0.5% to 4%
  • EXAMPLE 4 Hair Growth Stimulating Formulation for Topical Administration
  • [0038]
    Aloe Vera Gel 35% to 99%
    Minoxidil 1% to 5%
    Dimethyl Isosorbide 1% to 6%
    Rosemary Extract 2% to 8%
    Glycolic Acid 2% to 6%
    Pantothenic Acid 1% to 3%
    Glycerine 10% to 12%
    Safflower Oil 8% to 16%
    Capsaicin 0.5% to 2.5%
    Niacin 0.5% to 1.5%
    Ginkgo Biloba 1% to 3%
    Extract of Nettle Root 1% to 3%
    Horsetail Extract 2% to 4%
    Saw Palmetto Extract 3% to 8%
    Peppermint Oil 1% to 9%
    Milk Thistle 2% to 8%
    Methyl Nicotinate 0.5% to 4%
    Phospholipid 2% to 8%
  • EXAMPLE 5 Hair Growth Stimulating Formulation for Topical Administration
  • [0039]
    Aloe Vera Gel 35% to 99%
    Minoxidil 1% to 5%
    Capsaicin 0.5% to 2.5%
    Niacin 0.5% to 1.5%
    Ginkgo Biloba 1% to 3%
    Extract of Nettle Root 1% to 3%
    Saw Palmetto Extract 3% to 8%
    Peppermint Oil 1% to 9%
    Milk Thistle 2% to 8%
    Methyl Nicotinate 0.5% to 4%
    Phospholipid 2% to 8%
  • EXAMPLE 6 Hair Growth Stimulating Formulation for Topical Administration
  • [0040]
    pharmaceutically-acceptable 35% to 99%
    carrier
    Minoxidil 1% to 5%
    Extract of Nettle Root 1% to 3%
    Saw Palmetto Extract 3% to 8%
    phospholipid 2% to 8%
  • EXAMPLE 7 Hair Growth Stimulating Formulation for Topical Administration
  • [0041]
    pharmaceutically-acceptable 35% to 99%
    carrier
    Minoxidil 1% to 5%
    Extract of Nettle Root 1% to 3%
    Saw Palmetto Extract 3% to 8%
    Phospholipid 2% to 8%
    Niacin 0.5% to 1.5%
    Capsaicin 0.5% to 2.5%
  • EXAMPLE 8 Formulation for Dietary Supplement for Consumption in Conjunction with Topical Formulation
  • [0042]
    Niacin 30 mg
    Vitamin B6 25 mg
    Folate 200 mcg
    Biotin 130 mcg
    Panthothenic acid 30 mg
    Iodine 150 mcg
    Zinc 15 mg
    pumpkin seed concentrate 60 mg
    Ginkgo Biloba 30 mg
    Fo ti root 100 mg
    L-Histidine 50 mg
    Aloe vera gel 20 mg
    Gotu Kola leaf 30 mg
    Saw Palmetto berry 200 mg
    Nettle leaf 180 mg
    Sage leaf 20 mg
    Hawthorn berry 60 mg
    Bovine extract 30 mg
    Sulfur 20 mg
    Silica 25 mg
  • The above formulation is preferably put in tablet form. Preferably two tablets are taken twice a day concurrent with administration of topical formulations described in Examples 1-7 and elsewhere herein. [0043]
  • EXAMPLE 9 Topical Formulation
  • [0044]
    Aloe Vera Gel 35% to 99%
    Minoxidil 3% to 5%
    Rosemary Extract 0.5% to 1%
    Glycolic Acid 0.2% to 1%
    Tween 1% to 3%
    Glycerine-USP 5% to 7%
    Isopropyl alcohol 9% to 11%
    Capsaicin 1% to 2.5%
    Arlasolve DMI 0.6% to 1%
    Niacin 0.5% to 1.5%
    glycerol oxide esters 1% to 2%
    Ginkgo Biloba 1% to 3%
    Extract of Nettle Root 1% to 3%
    Horsetail Extract 1% to 2%
    Peppermint Oil 0.2% to 1%
    Milk Thistle 1% to 2%
    Glydant Plus 0.2%
    Methyl Nicotinate 0.05% to 1%
  • EXAMPLE 10 Clinical Study
  • Participants consisted of five males between the ages of 18 and 40, who were all experiencing hair loss of various degrees. The participants applied the formulation described in Example 9 to their scalps once daily, and ingested two tablets described in Example 8 twice daily. The scalps of the participants were evaluated every four weeks. Clinic follow up visits consisted of photographs, progress questionnaires completed by the participant, and study drug compliance. The results with respect to the amount of hair loss or initiation of new hair growth is noted below: [0045]
  • Two months—participants report slowing of hair loss and the beginning signs of new hair growth. [0046]
  • Three months—participants report no noticeable hair loss and new hair growth. Reports of new, “downy” type hair where topical solution has been applied were given. [0047]
  • Four months—participants report that hair is slowly getting thicker, and stronger. [0048]
  • Five months—participants fuller hair and definite reduction of hair loss. [0049]
  • Comments of hair growth with respect to location was dependent on the individual, location of each participant's hair loss, and where the topical solution was applied. Some participants reported hair growth in the apex area, as well as growth in the frontal region of the scalp. [0050]
  • It should be understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and the scope of the appended claims. [0051]
  • References
  • Brodland and Muller (1991) [0052] Cutis 47:173-176.
  • Katz, H. I. (1988) [0053] Clin. Dermatol., 6:195-199.
  • Puolakka, J. (1980) [0054] Acta. Obstet. Gynecol. Scand., suppl. 95:35-41.
  • Rushton, D. H., and D. D. Ramsay (1992) “The importance of adequate serum ferritin levels in cyproterone acetate and ethinyl-oestradiol therapy in women with diffuse androgen-dependent alopecia,” [0055] Clin. Endocrinol. 36:421-427.
  • Rushton, D. H., W. Futterwiet, D. H. Kingsley, P. Kingsley and M. J. Norris (1991) “Quantitative assessment of spironolactone treatment in women with diffuse androgen-dependent alopecia,” [0056] J. Soc. Cosmet. Chem. 42:317-325.
  • Zapacosta, A. R. (1980) [0057] N. Eng. J Med. 303:1480-1481.
  • U.S. Pat. No. 3,551,554 [0058]
  • U.S. Pat. No. 3,989,816. [0059]
  • U.S. Pat. No. 4,017,641. [0060]
  • U.S. Pat. No. 4,132,781. [0061]
  • U.S. Pat. No. 4,139,619. [0062]
  • U.S. Pat. No. 4,485,054. [0063]
  • U.S. Pat. No. 4,596,812. [0064]
  • U.S. Pat. No. 4,761,288. [0065]
  • U.S. Pat. No. 4,861,764. [0066]
  • U.S. Pat. No. 5,030,442. [0067]
  • U.S. Pat. No. 5,620,980. [0068]
  • PCT Application No. WO 92/16236. [0069]

Claims (18)

    What is claimed is:
  1. 1. A topical composition designed for application to the scalp, said composition comprising, in admixture with a pharmaceutically acceptable carrier and minoxidil, and one or more of the following:
    a.) saw palmetto extract;
    b.) nettle root extract;
    c.) Capsaicin;
    d.) Niacin;
    e.) Gingko Biloba;
    f.) horsetail extract;
    g.) phospolipid;
    h.) glycerol oxide esters;
    i.) cyclodextrin;
    j.) ketoconazole;
    k.) ursolic acid;
    l.) polysorbate;
    m.) 1,4,3,6 dianhydro-2,5,-di-o-methyl-D-glucitol;
    n.) peppermint oil;
    o.) silica;
    p.) milk thistle; or
    q.) methyl nicotinate.
  2. 2. The topical composition of claim 1, wherein said composition comprises a pharmaceutically acceptable carrier, minoxidil, nettle root extract, capsaicin, niacin, and horsetail extract.
  3. 3. The topical composition of claim 2, wherein minoxidil comprises about 1 percent to about 5 percent, nettle root extract comprises about 1 percent to about 3 percent, capsaicin comprises about 0.5 percent to about 2.5 percent, niacin comprises about 0.5 percent to about 2.0 percent and horsetail extract comprises about 2 percent to about 4 percent, by weight, of said composition.
  4. 4. The topical composition of claim 2 further comprising methyl nicotinate.
  5. 5. The topical composition of claim 4, further comprising phospholipid.
  6. 6. The topical composition of claim 1, wherein said composition comprises a pharmaceutically acceptable carrier, minoxidil, nettle root extract and phospholipid.
  7. 7. The topical composition of claim 6, wherein minoxidil comprises about 1 percent to about 5 percent, nettle root extract comprises about 1 percent to about 3 percent and phospholipid comprises about 2 percent to about 8 percent, by weight, of said composition.
  8. 8. The topical composition of claim 1, wherein minoxidil comprises about 1 percent to about 5 percent, by weight, of said composition.
  9. 9. The topical composition of claim 1, wherein said pharmaceutically acceptable carrier is water, glycols, esters, alcohols, lipids, or combinations thereof.
  10. 10. The topical composition of claim 9, wherein said pharmaceutically acceptable carrier is a mixture of isopropyl alcohol and glycerine.
  11. 11. A topical composition designed for application to the scalp, said composition comprising a mixture of minoxidil, saw palmetto extract, and nettle root extract.
  12. 12. A topical composition designed for application to the scalp, said composition comprising a mixture of ketoconazole; and saw palmetto extract or nettle root extract, or combinations thereof.
  13. 13. A topical composition designed for application to the scalp, said composition comprising a mixture of ursolic acid; and saw palmetto extract or nettle root extract, or combinations thereof.
  14. 14. A dietary supplement comprising minoxidil, saw palmetto extract, and nettle root extract
  15. 15. The dietary supplement of claim 14 further comprising one or more of the following components:
    (a) niacin;
    (b) vitamin B6;
    (c) folate;
    (d) biotin;
    (e) panthothenic acid;
    (f) iodine;
    (g) zinc;
    (h) pumpkin seed concentrate;
    (i) Ginkgo biloba;
    (j) fo ti root;
    (k) L-histidine;
    (l) aloe vera gel;
    (m) gotu kola leaf;
    (n) sage leaf;
    (o) Hawthorne berry;
    (p) bovine extract;
    (q) sulfur; or
    (r) silica.
  16. 16. A kit for stimulating hair growth comprising a container having the composition of claim 1 disposed therein and instructions for use.
  17. 17. A method of stimulating hair growth in a patient comprising obtaining a composition according to claim 2, and administering said composition to said patient's scalp.
  18. 18. The method of claim 17, further comprising co-administering, orally, the dietary supplement of claim 14, wherein co-administering occurs prior to, concurrently, or subsequent to said administering said composition.
US10624078 2000-02-18 2003-07-21 Compositions and methods for treating baldness Abandoned US20040096420A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US18355300 true 2000-02-18 2000-02-18
US09789294 US6596266B2 (en) 2000-02-18 2001-02-20 Compositions containing minoxidil and saw palmetto for treating baldness
US10624078 US20040096420A1 (en) 2000-02-18 2003-07-21 Compositions and methods for treating baldness

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10624078 US20040096420A1 (en) 2000-02-18 2003-07-21 Compositions and methods for treating baldness

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09789294 Continuation US6596266B2 (en) 2000-02-18 2001-02-20 Compositions containing minoxidil and saw palmetto for treating baldness

Publications (1)

Publication Number Publication Date
US20040096420A1 true true US20040096420A1 (en) 2004-05-20

Family

ID=26879264

Family Applications (2)

Application Number Title Priority Date Filing Date
US09789294 Expired - Fee Related US6596266B2 (en) 2000-02-18 2001-02-20 Compositions containing minoxidil and saw palmetto for treating baldness
US10624078 Abandoned US20040096420A1 (en) 2000-02-18 2003-07-21 Compositions and methods for treating baldness

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09789294 Expired - Fee Related US6596266B2 (en) 2000-02-18 2001-02-20 Compositions containing minoxidil and saw palmetto for treating baldness

Country Status (1)

Country Link
US (2) US6596266B2 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060120990A1 (en) * 2004-12-02 2006-06-08 Testa Hair Holdings Inc. Composition for treating hair and scalp and method for preparing same
WO2006066323A1 (en) * 2004-12-24 2006-06-29 Dolphst Pty Ltd Formulations and treatments for trichology
US20060148903A1 (en) * 2004-11-24 2006-07-06 Algorx Pharmaceuticals, Inc. Capsaicinoid gel formulation and uses thereof
US20070077222A1 (en) * 2005-10-03 2007-04-05 Shapiro Steven D Composition and treatment for hair loss
US20070293703A1 (en) * 2003-04-08 2007-12-20 Algorx Pharmaceuticals, Inc. Preparation and purification of synthetic capsaicin
US8985124B2 (en) 2005-10-03 2015-03-24 Pilaris Labs Llc Method for treatment of hair loss with a combination of natural ingredients
WO2018064233A1 (en) * 2016-09-27 2018-04-05 Shane Malek Pharmacokinetically extended action topical hair growth formulation, and administration method

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030054020A1 (en) * 2001-09-07 2003-03-20 Sarfaraz Niazi Method and composition for reducing sebum secretion in mammals
FR2849992B1 (en) * 2003-01-17 2007-03-16 Inst Phytoceutic A composition for oral administration containing capsaicinoids
WO2004068970A3 (en) * 2003-01-31 2006-03-09 George C Daher Means for improving the appearance of mammalian keratinous tissue
US20040254202A1 (en) * 2003-06-13 2004-12-16 The Procter & Gamble Company Method of promoting sleep using topical administration of vasoactive agents
EP1491202A1 (en) * 2003-06-23 2004-12-29 Polichem S.A. Nail restructuring compositions for topical application
EP2329831A3 (en) * 2003-11-05 2011-08-17 Osteoscreen, Inc. Stimulation of hair growth by Ginko biloba flavanoids
WO2005067873A1 (en) * 2003-12-22 2005-07-28 Regrowth, Llc Topical solutions comprising high concentrations of piperidinopyrimidine derivatives and methods of use thereof
US20050163811A1 (en) * 2004-01-23 2005-07-28 Richard Lee Topical solutions comprising high concentrations of piperidinopyrimidine derivatives and methods of use thereof
WO2005075449A1 (en) * 2004-02-03 2005-08-18 Yale University Compounds and methods to increase anti-p-glycoprotein activity of baicalein by alkylation on the a ring
DE102004009155A1 (en) * 2004-02-20 2005-09-01 Beiersdorf Ag Skin care product containing ursolic acid and ginkgo extract
FR2867973A1 (en) * 2004-03-26 2005-09-30 B Prince Sarl Lab Capillary care composition, useful to e.g. treat alopecia, comprises Sabal, which is an extract of Serenoa serrulata in association with a vehicle
US20050260152A1 (en) * 2004-05-03 2005-11-24 Jaghab Khalil C Hair growth composition
US20060009430A1 (en) * 2004-07-01 2006-01-12 Kelly Gregory J Composition for the prevention and treatment of the detrimental effects of dihydrotestosterone
US7238375B1 (en) * 2004-12-20 2007-07-03 Perry Stephen C Composition and method to promote human hair growth
US20070036742A1 (en) * 2005-08-09 2007-02-15 Access Business Group International Llc Methods and compositions for modulating hair growth or regrowth
US8197865B2 (en) * 2005-08-09 2012-06-12 Access Business Group International Llc Methods and compositions for modulating hair growth or regrowth
US20070081967A1 (en) * 2005-10-12 2007-04-12 John Cerullo Revitalizing hair follicles with total parenteral nutrition or hyperalimentation for maximum hair growth
US8147815B2 (en) * 2005-12-16 2012-04-03 Celmatrix Corporation Topical administration carrier composition and therapeutic formulations comprising same
RU2316334C2 (en) * 2005-12-19 2008-02-10 Медитек Индастриз ЛЛС Method for activating lost motor functions and determining their recovery effectiveness in central nervous system injury cases
US20070167899A1 (en) * 2006-01-19 2007-07-19 Strom Randy A Compression apparatus and method for stimulating hair growth
JP2009530369A (en) * 2006-03-21 2009-08-27 ヘオング ゲオン チョイ Natural herbal hair growth promoting composition and method of manufacturing
WO2007114825A1 (en) * 2006-04-05 2007-10-11 Regency Group Llc Bird repellant with sealant properties
DE102007009650A1 (en) * 2007-02-26 2008-08-28 Beiersdorf Ag Cosmetic combination product for improving the external appearance
US8580236B2 (en) * 2007-03-19 2013-11-12 Richard P. De Maria Hair sustaining formulation
DE102007045974A1 (en) * 2007-09-25 2009-04-09 Henkel Ag & Co. Kgaa Biotin and silica against aging hair
KR101372658B1 (en) * 2008-06-25 2014-03-14 이엘씨 매니지먼트 엘엘씨 Method and compositions for improving skin and body appearance
EP2344198A4 (en) * 2008-09-27 2013-01-09 Jina Pharmaceuticals Inc Lipid based pharmaceutical preparations for oral and topical application; their compositions, methods, and uses thereof
US20110112125A1 (en) * 2009-11-09 2011-05-12 Tritech Biopharmaceuticals Co., Ltd. Novel hair growth composition
US20110189114A1 (en) * 2010-01-29 2011-08-04 Nyangenya Maniga minoxidil composition and non-aerosol, non-spray foam method of delivery therefor
US9271917B2 (en) 2010-01-29 2016-03-01 Nyangenya Maniga Method and apparatus for delivery of a measured dosage of a non-aerosol, non-spray foam composition of minoxidil
CN104066424A (en) 2011-09-02 2014-09-24 伯特氏农场有限责任公司 Personal care compositions comprising squash or pumpkin extract
US8642097B1 (en) 2013-03-19 2014-02-04 Nyangenya Maniga Natural product energy drink and method of use thereof
US20150320710A1 (en) * 2014-05-12 2015-11-12 Susie Q, Ltd. Arginine-containing topical composition
WO2016186896A1 (en) * 2015-05-18 2016-11-24 Thrower Angelo Perry Hair regrowth treatment and growth stimulant
EP3320909A1 (en) * 2015-07-08 2018-05-16 Armesso Am España, S.L. Pharmaceutical composition that promotes capillary regeneration

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972345A (en) * 1999-05-03 1999-10-26 Chizick; Stephen Natural preparation for treatment of male pattern hair loss
US6149933A (en) * 1997-07-10 2000-11-21 Summa Rx Laboratories, Inc. Dietary supplement for promotion of healthy hair and pigment restoration
US6241987B1 (en) * 1998-08-20 2001-06-05 Amway Corporation Dietary supplement containing saw palmetto, pumpkin seed, and nettle root
US6284234B1 (en) * 1998-08-04 2001-09-04 Johnson & Johnson Consumer Companies, Inc. Topical delivery systems for active agents

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3551554A (en) 1968-08-16 1970-12-29 Crown Zellerbach Corp Enhancing tissue penetration of physiologically active agents with dmso
US4132781A (en) 1974-12-19 1979-01-02 Nelson Research & Development Company Method for treatment of acne
US4017641A (en) 1975-01-31 1977-04-12 The Procter & Gamble Company Skin moisturizing compositions containing 2-pyrrolidinone
US3989816A (en) 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4139619A (en) 1976-05-24 1979-02-13 The Upjohn Company 6-Amino-4-(substituted amino)-1,2-dihydro-1-hydroxy-2-iminopyrimidine, topical compositions and process for hair growth
US4596812A (en) 1976-05-24 1986-06-24 The Upjohn Company Methods and solutions for treating male pattern alopecia
US4082881A (en) 1976-12-23 1978-04-04 E. R. Squibb & Sons, Inc. Topical and other type pharmaceutical formulations containing isosorbide carrier
US5183817A (en) 1981-02-17 1993-02-02 Bazzano Gail S Combinations of retinoids and minoxidil-type compounds for hair growth
US4485054A (en) 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4761288A (en) 1984-09-24 1988-08-02 Mezei Associates Limited Multiphase liposomal drug delivery system
US4861764A (en) 1986-11-17 1989-08-29 Macro Chem. Corp. Percutaneous absorption enhancers, compositions containing same and method of use
US5030442A (en) 1987-03-30 1991-07-09 Liposome Technology, Inc. Non-crystalline minoxidil composition
US5026691A (en) 1987-03-30 1991-06-25 The Upjohn Company Combination of minoxidil and an antiinflammatory agent for treating patterned alopecia
US4828837A (en) 1987-03-30 1989-05-09 Liposome Technology, Inc. Non-crystalline minoxidil composition, its production and application
US5023090A (en) 1989-08-16 1991-06-11 Levin Robert H Topical compositions containing LYCD and other topically active medicinal ingredients for the treatment of ACNE
US5618798A (en) 1989-04-20 1997-04-08 Bar-Shalom; Daniel Use of sucralfate to treat baldness
DK0542802T3 (en) 1990-08-10 1996-07-22 Upjohn Co Stimulation of hair growth with potassium channel openers and 5alfa-reductase inhibitors
EP0576605A4 (en) 1991-03-19 1994-06-08 Vithal J Rajadhyaksha Compositions and method comprising aminoalcohol derivatives as membrane penetration enhancers
US5750107A (en) 1993-02-12 1998-05-12 Nomura; Manabu Hair growth promoter
JP3014214B2 (en) 1992-04-13 2000-02-28 鐘紡株式会社 Hair tonic cosmetics
US5407944A (en) 1993-02-19 1995-04-18 Goldman; Boris E. Compositions and methods for promoting hair growth
FR2706896B1 (en) 1993-06-23 1996-04-12 Caillot Jean Luc
FR2717683B1 (en) 1994-03-22 1996-06-28 Fabre Pierre Cosmetique hair composition based on minoxidil.
CA2145980C (en) 1994-03-31 2003-01-07 Shunsuke Takeda Hair revitalizing composition
US5609858A (en) 1994-11-22 1997-03-11 Buck; Carol J. Method for treatment of androgenic alopecia
US5620980A (en) 1995-02-22 1997-04-15 Macrochem Corporation Method for treating hair loss
FR2736824B1 (en) 1995-07-18 1997-10-10 Fabre Pierre Dermo Cosmetique capillary-based composition minoxidil low fat solvent content
US5750108A (en) 1995-09-18 1998-05-12 Regenix Marketing Systems, Inc. Hair treatment system and kit for invigorating hair growth
US5834014A (en) 1995-10-06 1998-11-10 The Regents Of The University Of Michigan Stimulation of hair follicles
US5763361A (en) 1995-10-23 1998-06-09 Merck & Co., Inc. 17-alkyl-7-substituted-4-aza steroid derivatives as 5-α-reductase inhibitors
EP0862556B1 (en) 1995-10-23 2001-09-05 MERCK & CO., INC. 17-alkyl-7-substituted-4-aza steroid derivatives
GB2314019B (en) 1996-06-10 2000-03-15 Bio Scient Ltd The use of L-Lysine in the treatment of hair loss
US6193976B1 (en) * 1999-05-25 2001-02-27 Nupel, Inc. Hair restorer containing vetiver grass extract

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6149933A (en) * 1997-07-10 2000-11-21 Summa Rx Laboratories, Inc. Dietary supplement for promotion of healthy hair and pigment restoration
US6284234B1 (en) * 1998-08-04 2001-09-04 Johnson & Johnson Consumer Companies, Inc. Topical delivery systems for active agents
US6241987B1 (en) * 1998-08-20 2001-06-05 Amway Corporation Dietary supplement containing saw palmetto, pumpkin seed, and nettle root
US5972345A (en) * 1999-05-03 1999-10-26 Chizick; Stephen Natural preparation for treatment of male pattern hair loss

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070293703A1 (en) * 2003-04-08 2007-12-20 Algorx Pharmaceuticals, Inc. Preparation and purification of synthetic capsaicin
US20060148903A1 (en) * 2004-11-24 2006-07-06 Algorx Pharmaceuticals, Inc. Capsaicinoid gel formulation and uses thereof
US20060120990A1 (en) * 2004-12-02 2006-06-08 Testa Hair Holdings Inc. Composition for treating hair and scalp and method for preparing same
US7205009B2 (en) 2004-12-02 2007-04-17 Dirk Stass Composition for treating hair and scalp and method for preparing same
WO2006066323A1 (en) * 2004-12-24 2006-06-29 Dolphst Pty Ltd Formulations and treatments for trichology
US8440239B2 (en) 2004-12-24 2013-05-14 Dolphst Pty Ltd. Formulations and treatments for trichology
US20070077222A1 (en) * 2005-10-03 2007-04-05 Shapiro Steven D Composition and treatment for hair loss
US8985124B2 (en) 2005-10-03 2015-03-24 Pilaris Labs Llc Method for treatment of hair loss with a combination of natural ingredients
US9532941B2 (en) 2005-10-03 2017-01-03 Pilaris Labs Llc Method for treatment of hair loss with a combination of natural ingredients
WO2018064233A1 (en) * 2016-09-27 2018-04-05 Shane Malek Pharmacokinetically extended action topical hair growth formulation, and administration method
US9962444B2 (en) 2016-09-27 2018-05-08 Shane Malek Pharmacokinetically extended action topical hair growth formulation, and administration method

Also Published As

Publication number Publication date Type
US20020028257A1 (en) 2002-03-07 application
US6596266B2 (en) 2003-07-22 grant

Similar Documents

Publication Publication Date Title
US6358541B1 (en) Topical preparation for the treatment of hair loss
US5425954A (en) Topical amino acid - vitamin complex compositions for pharmaceutical and cosmetic use
US6447762B1 (en) Hair lotion useful for treatment of hair loss and stimulating hair growth
US7001594B1 (en) Scalp cosmetic compositions and corresponding methods of application to provide scalp moisturization and skin active benefits
US20020182162A1 (en) Nitric oxide (NO) donor+cGMP-PDE5 inhibitor as a topical drug for enhanced hair growth
EP0336812B1 (en) Association of pyrimidine derivatives and urea and/or allantoin derivatives to induce and stimulate hair growth and to reduce hair loss
US20050136085A1 (en) Panthenol and natural organic extracts for reducing skin irritation
US6231875B1 (en) Acidified composition for topical treatment of nail and skin conditions
US6333057B1 (en) Composition and method for topical treatment of androgenic alopecia
US4034114A (en) Treatment of skin keratoses with retinal
EP0415598A1 (en) Cosmetic composition
US6420352B1 (en) Hair loss prevention
US20060008538A1 (en) Methods of treating the skin
EP0403238A2 (en) Cosmetic composition
US6403654B1 (en) Compositions for and method of treatment for psoriasis
WO1999032072A1 (en) Compositions and methods for treatment of alopecia
JP2005314323A (en) Hair growth formulation
US5620980A (en) Method for treating hair loss
US4039664A (en) Topical griseofulvin composition and method
US5358714A (en) Cosmetic composition
US20050163811A1 (en) Topical solutions comprising high concentrations of piperidinopyrimidine derivatives and methods of use thereof
US20030007941A1 (en) Method of treating hair loss using thyromimetic compounds
US20040213859A1 (en) Organic nutrient for hair loss treatment
WO1992000057A1 (en) Method of treating alopecia
JPH11116446A (en) External preparation for head